22261-05-8Relevant academic research and scientific papers
INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE
-
Paragraph 0608, (2021/03/13)
Disclosed herein are compounds which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1 -mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer.
Selective Activation of Human Caseinolytic Protease P (ClpP)
Stahl, Matthias,Korotkov, Vadim S.,Balogh, Dóra,Kick, Leonhard M.,Gersch, Malte,Pahl, Axel,Kielkowski, Pavel,Richter, Klaus,Schneider, Sabine,Sieber, Stephan A.
supporting information, p. 14602 - 14607 (2018/09/25)
Caseinolytic protease P (ClpP) is the proteolytic component of the ClpXP protein degradation complex. Eukaryotic ClpP was recently found to act within the mitochondria-specific unfolded protein response (UPRmt). However, its detailed function a
Preparation of 1,3,4-Oxadiazol-2-carboxylic Acid Derivatives
Dost, J.,Heschel, M.,Stein, J.
, p. 109 - 116 (2007/10/02)
The synthesis of 5-substituted-1,3,4-oxadiazol-2-carboxylic acid derivatives 3a-g and 4a-g by cyclodehydratation of diacylhydrazines 1a-g and 2a-g are described.Further derivatives 6 to 9 are obtained from 1,3,4-oxadiazol-2-carboxethyl esters 3.
